… Axiomer Investor Call ProQR management will host an investor … conference call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the … the presentation date. Download the presentation About Axiomer ® ProQR is pioneering a next-generation RNA editing …
… Investor/Analyst Webcast: Lilly Partnership Expansion and Axiomer Overview ProQR Management will host an investor … conference call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the … 30 days following the presentation date. About Axiomer ® ProQR is pioneering a next-generation RNA base …
… the event, the Company will showcase its proprietary Axiomer ® RNA-editing technology platform, announce initial … and mentored over 50 Ph.D. and M.S. degree students. About Axiomer ® ProQR is pioneering a next-generation RNA base editing technology called Axiomer ® , which could potentially yield a new class of …
… ProQR Therapeutics Date: Thursday, March 23 Abstract: Axiomer, an RNA editing platform, uses chemically modified … and the presentation will review the potential of Axiomer platform in multiple organs as well as its …
ProQR shared additional analyses from the Phase 2/3 Illuminate trial of sepofarsen for LCA10 and provided an update on the company strategy. Management to host a conference call today at 8:00am EDT (14:00 CET).
ProQR will host a virtual Investor and Analyst Event highlighting its pipeline entitled:
“Expanding the Axiomer™ RNA Editing Opportunity Beyond AX-0810”
ProQR will present new preclinical data for Axiomer, including the first preclinical data for its AX-0810 pipeline program for cholestatic diseases targeting NTCP at the ASGCT Annual Meeting, May 7-11, 2024, in Baltimore, Maryland.